Each lot of this antibody is quality control tested by ELISA assay. For ELISA applications, a concentration range of 1-4 μg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
ELISA or ELISPOT Capture1-4: The purified JES3-19F1 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502/501503) as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture. Neutralization1,2: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm sterile-filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. No. 506810). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining5,6 of paraformaldehyde-fixed, saponin-treated frozen tissue sections, and immunocytochemistry. Note: For testing human IL-10 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430601 to 430606) are specially developed and recommended.
Application References:
1. Abrams, J., et al., 1992. Immunol. Rev. 127: 5. 2. Gotlieb, W., et al., 1992. Cytokine 4: 385. 3. Yssel, H., et al., 1992. J. Immunol. 149: 2378. 4. Burdin, N., et al., 1993. J. Exp. Med. 177: 295. 5. Andersson, U., et al., 1999. Detection and quantification of gene expression. New York: Springer-Verlag. 6. Andersson, J., et al., 1994. Immunology 83: 16.
Description:
IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production. The JES3-19F1 antibody reacts with human and viral interleukin-10 (IL-10). The JES3-19F1 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Other Names:
Interleukin-10, B cell derived T cell growth factor (B-TCGF), Cytokine synthesis inhibitory factor (CSIF), T-cell growth inhibitory factor (TGIF)
Structure:
Acid-labile cytokine; dimer; 35-40 kD (Mammalian)
Regulation:
Production inhibited by IL-4, IL-10
Cellular Sources:
Activated CD8+ and CD4+ T cells, activated monocytes, mast cells, Ly-1 B (mouse)
Cellular Targets:
T cells, B cells, mast cells, macrophages
Receptors:
IL-10R (CDw210)
Bioactivity/Activities:
Inhibit IFN-γ, TNF-β, IL-2 production by TH1 clones; inhibits macrophage-mediated IL-1, IL-6, TNF-α synthesis; suppress delayed type hypersensitivity response; stimulate TH2 cell response; mast cell proliferation in
Antigen References:
1. Fitzgerald, K., et al., Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. de Waal-Malefyt, R., et al., 1992. Curr. Opin. Immunol. 4:314. 3. Howard, M., et al., 1992. Immunol. Today. 13:198. 4. Quesniaux, V. 1992. Research Immunol. 143:385.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
